Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with 'curative' intent
Autor: | P. Romanelli, Marta Scorsetti, Andrei Fodor, Giovanni Ivaldi, Olga Oneta, Barbara Alicja Jereczek-Fossa, Isa Bossi Zanetti, G. Catalano, Stefano Maria Magrini, Michela Buglione, Giancarlo Beltramo, Paolo Antognoni, Nadia Di Muzio, Marianna Alessandra Gerardi, Davide Tomasini, Antonio Laudati, Paolo Borghetti, Davide Franceschini, Marco Lorenzo Bonù, Ciro Franzese, Italo Dell'Oca |
---|---|
Přispěvatelé: | Buglione, M., Jereczek-Fossa, B. A., Bonu, M. L., Franceschini, D., Fodor, A., Zanetti, I. B., Gerardi, M. A., Borghetti, P., Tomasini, D., Di Muzio, N. G., Oneta, O., Scorsetti, M., Franzese, C., Romanelli, P., Catalano, G., Dell'Oca, I., Beltramo, G., Ivaldi, G. B., Laudati, A., Magrini, S. M., Antognoni, P. |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment non-small cell lung cancer (NSCLC) Adenocarcinoma of Lung Ablative treatments Radiosurgery Metastasis Stereotactic radiosurgery (SRS) 03 medical and health sciences 0302 clinical medicine Non small cell lung cancer (NSCLC) Carcinoma Non-Small-Cell Lung Medicine Humans Progression-free survival Lung cancer Aged Retrospective Studies Aged 80 and over Univariate analysis Oligometastasis business.industry Stereotactic radiotherapy (SRT) Middle Aged medicine.disease Prognosis Combined Modality Therapy Radiation therapy Survival Rate 030104 developmental biology Oncology 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female Radiology Dose Fractionation Radiation business Brain metastasis Follow-Up Studies |
Zdroj: | Lung cancer (Amsterdam, Netherlands). 141 |
ISSN: | 1872-8332 |
Popis: | Objectives: stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) are a therapeutic option for Oligometastatic/Oligoprogressive (OM/OP) NSCLC. This retrospective multicentre analysis aims to analyse clinical outcomes and treatment related toxicity of patients treated to all sites of know disease with SRS and/or FSRT for OM/OP NSCLC in 8 Italian radiation oncology centres. Materials and methods: From January 2016 to January 2017 198 OM/OP NSCLC patients (pts) were treated in 8 Centres. Inclusion criteria were as follows: 1–5 lesions at onset or after previous systemic treatment; Pts must have all metastatic lesions treated. Endpoints analysed were local progression free survival (LPFS); out-of-field recurrence free survival (OFPS); progression free survival (PFS); overall survival (OS). Time to New systemic Therapy free survival (TNT) and toxicity were also analysed. Results: At the time of radiotherapy, 119 pts (60 %) were treated for a single lesion, 49 (25 %) for 2 lesions, 30 (15 %) for 3–5 metastases. Total number of lesions treated was 333: 204 brain, 68 lung, 24 bone, 16 nodal, 12 adrenal, 8 liver and 1 soft tissue. 83/198 pts (41.8 %) had the primary tumour controlled at the time of the SRT. After a median follow-up of 18 months, median OS and PFS were 29.6 months and 10.6 months, respectively. One year LPFS and OPFS were 90 % and 47 %, respectively. Median TNT was 10 months. At univariate analysis factors associated with better OS were PS 0–1; controlled primary tumour, 1–2 lesions; extracranial metastasis. Multivariate analysis confirmed number of lesions |
Databáze: | OpenAIRE |
Externí odkaz: |